Product Pathways - Cell Cycle / Checkpoint
SignalSilence® CK2α siRNA I #6389
|6389S||300 µl (3 nmol)||---||In Stock||---|
|6389||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® CK2α siRNA I (+), using CK2α Antibody #2656 and α-Tubulin (11H10) Rabbit mAb #2125. The CK2α Antibody confirms silencing of CK2α expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.
SignalSilence® CK2α siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit CK2α expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM CK2α siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
CK2 (formerly called Casein Kinase II) is a highly conserved protein kinase with more than 300 substrates regulating cell growth, cell death, and cell survival. CK2 has been implicated in the response to UV irradiation-induced DNA damage, targeting XRCC1 (1) and BRCA1 (2) as well as regulating p53 tumor suppressor protein functions (3). Furthermore, CK2 plays a key role in NF-κB activation (4). UV irradiation stimulates CK2-mediated phosphorylation of several carboxy-terminal residues within IκBα, resulting in IκBα proteasomal degradation and the release and nuclear translocation of active NF-κB. CK2 is also dysregulated in many cancers (5) and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases (6). Structurally, CK2 is a multimeric protein complex consisting of two catalytic subunits (α or α') and two regulatory β subunits (7). CK2 is distributed ubiquitously and is apparently constitutively active (7). While cell cycle-dependent Ser-Pro phosphorylation sites have been identified on CK2α and CK2β, Tyr255 phosphorylation by the Src-related kinase c-Fgr seems to have the greatest effect on CK2α activity (8,9).
- Morales, J.C. and Carpenter, P.B. (2004) Sci Aging Knowledge Environ 2004, pe24.
- O'Brien, K.A. et al. (1999) Biochem Biophys Res Commun 260, 658-64.
- Cox, M.L. and Meek, D.W. (2010) Cell Signal 22, 564-71.
- Dominguez, I. et al. (2009) Cell Mol Life Sci 66, 1850-7.
- Trembley, J.H. et al. Biofactors 36, 187-95.
- Perez, D.I. et al. (2010) Med Res Rev, Epub ahead of print.
- Bosc, D.G. et al. (1995) J Biol Chem 270, 25872-8.
- Donella-Deana, A. et al. (2003) Biochem J 372, 841-9.
- Litchfield, D.W. (2003) Biochem J 369, 1-15.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.